The company has secured 506 marketing approvals for its oncology products across 76 countries.
Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits
Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Subscribe To Our Newsletter & Stay Updated
